User:Mr. Ibrahem/Moexipril
 | |
| Clinical data | |
|---|---|
| Trade names | Univasc |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a695018 |
| Routes of administration | By mouth |
| Drug class | ACE inhibitor[1] |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | 13-22% |
| Protein binding | 90% |
| Metabolism | Liver (active metabolite, moexiprilat) |
| Onset of action | With an hour[1] |
| Elimination half-life | 1 hour; 2-9 hours (active metabolite) |
| Duration of action | About a day[1] |
| Excretion | 50% (faeces), 13% (urine) |
| Identifiers | |
| |
| Chemical and physical data | |
| Formula | C27H34N2O7 |
| Molar mass | 498.576 g·mol−1 |
  (what is this?) (verify) | |
Moexipril, sold under the brand name Univasc among others, is a medication used to treat high blood pressure, heart failure, and diabetic kidney disease.[1] It can be given alone or with other medications.[1] It is taken by mouth.[1] Effects begin within an hour and last about a day.[1]
Common side effects include cough, dizziness, tiredness, rash, and muscle pain.[1] Other side effects may include angioedema, high potassium, low blood pressure, and kidney problems.[1] Use in pregnancy may harm the baby.[1] It is an angiotensin converting enzyme inhibitor (ACE inhibitor).[1]
Moexipril was patented in 1980 and approved for medical use in 1995.[2] It is available as a generic medication.[3] In the United States 3 months of 15 mg per day costs about 33 USD.[3] It appears to work less well in Black people.[1]
References[edit]
- ^ a b c d e f g h i j k l m n o "Moexipril Monograph for Professionals". Drugs.com. Archived from the original on 21 January 2021. Retrieved 18 November 2021.
- ^ Fischer, Jnos; Ganellin, C. Robin (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 468. ISBN 9783527607495. Archived from the original on 2020-10-18. Retrieved 2021-07-05.
- ^ a b "Moexipril Prices, Coupons & Savings Tips - GoodRx". GoodRx. Archived from the original on 7 November 2016. Retrieved 18 November 2021.